# A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants

> **NCT06710925** · PHASE3 · COMPLETED · sponsor: **Zhuhai Trinomab Pharmaceutical Co., Ltd.** · enrollment: 315 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** TNM001
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT06710925
- **Lead sponsor:** Zhuhai Trinomab Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-28
- **Primary completion:** 2025-07-27
- **Final completion:** 2025-12-14
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06710925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06710925, "A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06710925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*